Search results (279)
« Back to PublicationsLongitudinal changes in cardiopulmonary outcomes of adults born extremely prematurely: United Kingdom Oscillation Study
Journal article
Jenkinson A. et al, (2026), Pediatric Research, 99, 106 - 111
Respiratory Clinicians’ Views on Offering “Rescue Packs” to Patients Discharged After COPD Exacerbation: Qualitative Interview Study
Journal article
Kuberska K. et al, (2025), COPD: Journal of Chronic Obstructive Pulmonary Disease, 22
Fractional exhaled nitric oxide and the response to prednisolone for asthma attacks in patients treated with anti-IL5/5Rα therapy: a prospective observational study
Journal article
Howell I. et al, (2025), European Respiratory Journal, 66, 2501229 - 2501229
Rebranding COPD Care and Research in the 21st Century
Journal article
Soriano JB. et al, (2025), Respirology, 30, 1025 - 1028
The Risk–Benefit Balance of Oral Corticosteroid Treatment for Asthma Attacks: A Discrete Choice Experiment of Patients and Healthcare Professionals in the UK and New Zealand
Journal article
Howell I. et al, (2025), Respirology, 30, 1035 - 1045
Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial
Journal article
Martinez FJ. et al, (2025), ERJ Open Research, 11, 00324 - 2025
anslational view of airway epithelial dysfunction in COPD
Journal article
Brightling CE. et al, (2025), European Respiratory Review, 34, 250110 - 250110
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial
Journal article
Christenson SA. et al, (2025), The Lancet Respiratory Medicine, 13, 687 - 697
Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS
Journal article
Singh D. et al, (2025), Respiratory Research, 26
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores
Journal article
Vogelmeier CF. et al, (2025), Respiratory Medicine, 241, 108015 - 108015
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
Journal article
Sciurba FC. et al, (2025), New England Journal of Medicine, 392, 1710 - 1720
Inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review and meta-analysis on mortality protection - making a long story short
Journal article
Rogliani P. et al, (2025), Expert Review of Respiratory Medicine, 19, 245 - 255
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials
Journal article
Bhatt SP. et al, (2025), The Lancet Respiratory Medicine, 13, 234 - 243
Readability and complexity of written information presented to hospitalised patients for trial consent during the COVID-19 pandemic in the UK: a retrospective document analysis
Journal article
Gourlay E. et al, (2025), BMJ Open, 15, e089447 - e089447
Oral Corticosteroid-Related Healthcare Resource Utilization and Associated Costs in Patients with COPD
Journal article
Tse G. et al, (2025), Advances in Therapy, 42, 375 - 394